市場調查報告書
商品編碼
1461510
全球生物製藥市場規模、佔有率、成長分析、按產品類型、按應用、按最終用途 - 行業預測,2024-2031 年Global Biopharmaceuticals Market Size, Share, Growth Analysis, By By Product type(Monoclonal Antibodies, Gene Therapies), By Application(Oncology, Inflammatory Diseases), By End-use(Health And Care, Biopharma Companies) - Industry Forecast 2024-2031 |
2022年全球生物製藥市場價值約3.7787億美元,較2023年的4.0734億美元有所成長,預測期內(2024-2031年)年複合成長率為7.80%,預計到2031年將達到7.4287億美元。
生物製藥公司向其他生物製藥公司提供包裝和藥物製造等合約服務,使大型生物製藥公司能夠簡化製造流程並專注於藥物發現和行銷。由於內部生產能力有限,較小的生物技術公司通常將填充和成品製造外包,這有助於減少資本支出。源自生物技術的生物製藥利用直接從生物來源(主要是活生物體,包括被稱為基因改造生物的基因改造動物和植物)提取的蛋白質和核酸,這仍然存在爭議和實驗性。核准的生物製藥中值得注意的是重組人類胰島素,目前市面上有近300種產品。市場成長是由人口老化、醫療保健意識提高和醫療成本上升等因素推動的,而新生物製藥的持續研發和核准預計將進一步推動市場擴張。然而,該行業面臨重大挑戰,特別是這些藥物的高成本,需要大幅降低成本以確保業務永續性。
Global Biopharmaceuticals Market was valued around USD 377.87 million in 2022 and is expected to rise from USD 407.34 million in 2023 to reach USD 742.87 million by the end of 2031, by recording a CAGR of 7.80% during the forecast period (2024-2031).
A biopharmaceutical company offers contract services to other biopharmaceutical firms, encompassing packaging and drug manufacturing, thereby allowing larger biopharmaceutical entities to streamline their manufacturing processes and focus on drug discovery and marketing. Small biotechnology companies often outsource fill and finish manufacturing due to limited in-house production capacity, aiding in reducing capital expenditures. Biopharmaceuticals, derived from biotechnology, utilize proteins and nucleic acids extracted directly from biological sources, primarily living organisms including genetically modified plants and animals known as transgenic organisms, although this method remains contentious and experimental. Notable among approved biopharmaceuticals is recombinant human insulin, with nearly 300 such products currently available. Market growth is driven by factors such as an aging population, increased healthcare awareness, and rising healthcare costs, with ongoing research and development and approval for newer biopharmaceutical products expected to further propel market expansion. Nevertheless, the industry faces significant challenges, notably the high cost of these drugs, necessitating substantial reduction to ensure business sustainability.
Top-down and bottom-up approaches were used to estimate and validate the size of the global biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biopharmaceuticals Market Segmental Analysis
The global biopharmaceuticals market is segmented on the basis of product type, application, end use, and region. With respect to segmentation by product type, the market is segmented into the Monoclonal Antibodies, Gene Therapies, Thrombolytics and Anticoagulants, and Recombinant Protein. Based on classification by application, the market is categorized into Oncology, Inflammatory Diseases, Cardiology, Neurology, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, and Others. With respect to categorization by end use, the market is grouped into Health and Care, Biopharma Companies, Diagnostic Labs, Clinical Research Institute, Clinical Research Organizations (CROs), and Others. Region wise, the market is widespread into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.
Drivers of the Global Biopharmaceuticals Market
Globally, chronic illnesses like cancer, diabetes, and heart disease pose significant threats to health and well-being, with the World Health Organization projecting cancer to be responsible for nearly one-sixth of all deaths by 2020. Biopharmaceuticals leveraging protein-based therapies have emerged as effective treatments for various cancers, yet challenges persist due to factors such as increased tobacco usage, unhealthy dietary habits, excessive alcohol consumption, and sedentary lifestyles. Cardiovascular disease, a leading cause of mortality, claims lives every second in the United States alone, spurring innovation in the field, exemplified by companies like Invizius and 3P Biopharmaceuticals developing groundbreaking technologies to aid cardiovascular patients undergoing hemodialysis. With the prevalence of chronic diseases on the rise globally, the biopharmaceutical market is poised for significant expansion between 2024 and 2031.
Restraints in the Global Biopharmaceuticals Market
Due to the combination of low incomes and the heavy burden of healthcare expenses, individuals in developing nations face significant barriers in affording biomedicines and therapies, potentially hindering market expansion in the foreseeable future. According to the United Nations Development Program, as of 2020, 1.3 billion people, equivalent to 22% of the global population, live in poverty, limiting their access to adequate healthcare services due to financial constraints. Additionally, lacking robust healthcare infrastructure, half of the world's population is unable to avail themselves of essential medical facilities, as reported by the World Health Organization. These challenges collectively impact the biopharmaceuticals market, posing considerable difficulties for its growth trajectory.
Market Trends of the Global Biopharmaceuticals Market
The rapid growth of the biopharmaceuticals market is predominantly fueled by the effective utilization of monoclonal antibodies and their derivatives in therapeutic treatments. Various ailments such as cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases have benefited from these antibodies' therapeutic potential. The global healthcare systems have been under immense pressure due to the COVID-19 pandemic, prompting relentless efforts from researchers worldwide to address this escalating challenge. Consequently, there's an anticipated surge in demand for COVID-19-specific monoclonal antibodies to mitigate the impact of the pandemic.